company background image
ALCL

Cellectis ENXTPA:ALCLS Stock Report

Last Price

€3.27

Market Cap

€148.8m

7D

-1.5%

1Y

-74.7%

Updated

24 May, 2022

Data

Company Financials +
ALCLS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ALCLS Stock Overview

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

Cellectis Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cellectis
Historical stock prices
Current Share Price€3.27
52 Week High€13.81
52 Week Low€2.68
Beta2.3
1 Month Change-10.07%
3 Month Change-17.13%
1 Year Change-74.65%
3 Year Change-78.63%
5 Year Change-84.92%
Change since IPO-77.85%

Recent News & Updates

Shareholder Returns

ALCLSFR BiotechsFR Market
7D-1.5%0.4%-2.9%
1Y-74.7%-42.0%-6.3%

Return vs Industry: ALCLS underperformed the French Biotechs industry which returned -39.9% over the past year.

Return vs Market: ALCLS underperformed the French Market which returned -18.8% over the past year.

Price Volatility

Is ALCLS's price volatile compared to industry and market?
ALCLS volatility
ALCLS Average Weekly Movement12.1%
Biotechs Industry Average Movement8.7%
Market Average Movement6.0%
10% most volatile stocks in FR Market10.1%
10% least volatile stocks in FR Market3.5%

Stable Share Price: ALCLS is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ALCLS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
1999297Andre Choulikahttps://www.cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Cellectis Fundamentals Summary

How do Cellectis's earnings and revenue compare to its market cap?
ALCLS fundamental statistics
Market CapUS$159.68m
Earnings (TTM)-US$134.24m
Revenue (TTM)US$41.41m

3.9x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALCLS income statement (TTM)
RevenueUS$41.41m
Cost of RevenueUS$23.60m
Gross ProfitUS$17.81m
Other ExpensesUS$152.05m
Earnings-US$134.24m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.95
Gross Margin43.01%
Net Profit Margin-324.18%
Debt/Equity Ratio10.1%

How did ALCLS perform over the long term?

See historical performance and comparison

Valuation

Is Cellectis undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


0.84x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALCLS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALCLS's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALCLS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: ALCLS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALCLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALCLS is good value based on its Price-To-Book Ratio (0.8x) compared to the FR Biotechs industry average (2.6x).


Future Growth

How is Cellectis forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


48.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALCLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALCLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALCLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALCLS's revenue (46.9% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALCLS's revenue (46.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALCLS is forecast to be unprofitable in 3 years.


Past Performance

How has Cellectis performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-9.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALCLS is currently unprofitable.

Growing Profit Margin: ALCLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALCLS is unprofitable, and losses have increased over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare ALCLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALCLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: ALCLS has a negative Return on Equity (-71.17%), as it is currently unprofitable.


Financial Health

How is Cellectis's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALCLS's short term assets ($195.2M) exceed its short term liabilities ($52.3M).

Long Term Liabilities: ALCLS's short term assets ($195.2M) exceed its long term liabilities ($91.8M).


Debt to Equity History and Analysis

Debt Level: ALCLS has more cash than its total debt.

Reducing Debt: ALCLS's debt to equity ratio has increased from 0% to 10.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALCLS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALCLS has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 24.8% each year.


Dividend

What is Cellectis's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALCLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALCLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALCLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALCLS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALCLS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Andre Choulika (56 yo)

23.33yrs

Tenure

US$879,062

Compensation

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. Dr. Choulika is a pioneer in the...


CEO Compensation Analysis

Compensation vs Market: Andre's total compensation ($USD879.06K) is above average for companies of similar size in the French market ($USD399.32K).

Compensation vs Earnings: Andre's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ALCLS's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: ALCLS's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cellectis S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cellectis S.A.
  • Ticker: ALCLS
  • Exchange: ENXTPA
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €148.820m
  • Shares outstanding: 45.51m
  • Website: https://www.cellectis.com

Number of Employees


Location

  • Cellectis S.A.
  • 8, rue de la Croix Jarry
  • Paris
  • Ile-de-France
  • 75013
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.